Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
60.3 ^USD	-0.95%		-3.41%	-3.98%

Apr. 22	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	MT
Mar. 31	Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	CI

Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 09, 2022 at 04:09 pm EDT

Vaxcyte, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 38.99 million compared to USD 21.22 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.41 a year ago.

Latest news about Vaxcyte, Inc.

Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	Apr. 22	MT
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30	CI
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30	CI
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30	CI
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	Mar. 21	MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating	Mar. 12	MT
Transcript : Vaxcyte, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM	Mar. 12
Transcript : Vaxcyte, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	Mar. 04	CI
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating	Feb. 28	MT
Vaxcyte Q4 Loss Widens	Feb. 27	MT
Transcript : Vaxcyte, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	Feb. 02	MT
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	Jan. 31	MT
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	Jan. 31	MT
Vaxcyte Prices $750 Million Public Offering at $64 Per Share	Jan. 31	MT
Vaxcyte Launches Securities Offering; Shares Fall After Hours	Jan. 30	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Jan. 29	MT
Vaxcyte Shares Rise After Completion of Enrollment for Phase 1/2 Clinical Study Assessing Vaccine Candidate	Jan. 29	MT
Vaxcyte Completes Enrollment for Phase 1/2 Clinical Study Assessing Pneumococcal Conjugate Vaccine Candidate	Jan. 29	MT
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older	Jan. 29	CI
Vaxcyte Insider Sold Shares Worth $958,783, According to a Recent SEC Filing	Jan. 25	MT
Vaxcyte Insider Sold Shares Worth $485,879, According to a Recent SEC Filing	Jan. 19	MT
Vaxcyte Names Chief People Officer	Jan. 16	MT

Chart Vaxcyte, Inc.

Duration

Period

More charts

Company Profile

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

60.3 USD

Average target price

103.3 USD

Spread / Average Target

+71.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VAXCYTE, INC.	-3.98%	6.56B
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs